Resistance to Tyrosine Kinase Inhibitors in EGFR-mutant of Non-Small Cell Lung Cancer

Fariz Nurwidya, Akiko Murakami, Fumiyuki Takahashi, Faisal Yunus, Kazuhisa Takahashi

Research output: Contribution to journalArticlepeer-review

Abstract

The epidermal growth factor receptor (EGFR) pathway plays a crucial role in nonsmallcell lung cancer (NSCLC), contributing to a number of highly relevant processes in tumordevelopment and progression, including cell proliferation, regulation of apoptotic cell deathand angiogenesis that leads to tumor growth and metastatic spread. Accordingly, targetingEGFR has been intensely pursued, with the development of series of promising molecular inhibitors for use in clinical oncology. In recent years, tyrosine kinase (TK) domain of the EGFR was discovered in patients with NSCLC and has given a dramatic clinical response to treatment with TK inhibitors (TKIs) such as gefitinib. However, molecular studies and clinical trials have demonstrated the occurrence of primary and/or secondary resistance to these drugs. A greater understanding of these mechanisms that lead to EGFR resistance may provide valuable insights to help design new strategies that will enhance the impact of this promising class of inhibitors for the treatment of patients with NSCLC. J Indon Med Assoc. 2011;61:493-7.
Original languageEnglish
JournalJournal of the Indonesian Medical Association
Publication statusPublished - Dec 2011

Fingerprint

Dive into the research topics of 'Resistance to Tyrosine Kinase Inhibitors in EGFR-mutant of Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this